Event-free survival (EFS) improved by 60% and overall survival (OS) by 50% with the antibody-drug conjugate (ADC) enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) versus upfront radical ...

Across several clinical outcomes, including 28-day mortality, beta-blocker esmolol was more effective than standard care and ...

At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing loca ...

With age comes wisdom. And wrinkles. And joint pain. In wellness circles, the buzz is that collagen supplements can help with ...

The phase 3 DREAM3R study randomized patients 2:1 to receive durvalumab 1500 mg every 3 weeks plus chemotherapy every 3 weeks for 4 to 6 cycles, followed by durvalumab maintenance 1500 mg every 4 ...

In phase 3 DREAM3R, first-line Imfinzi plus chemotherapy showed survival and response benefits in advanced mesothelioma, but results were inconclusive.

Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria remission (UPCR =0.5 g/g) achieved in one-third of pat ...

Tislelizumab addition to CRT improved survival in ESCC, with group B showing a 1-year PFS rate of 73% and OS rate of 85%. The trial's primary endpoint was PFS, with secondary endpoints including OS, ...

Taking a certain form of Vitamin D could have a negative effect, a new study suggests. Vitamin D3 (cholecalciferol) is the ...

Marlborough: Boston Scientific Corporation has announced it has entered into a definitive agreement to acquire Nalu Medical, ...

A sweeping review of over 200 studies finds that aerobic exercises like walking and cycling offer the best pain relief and ...

Trastuzumab botidotin is a HER2-targeted ADC composed of a cytotoxic drug (Duostatin-5, anti-microtubule agent) with ...